IP Library Granted Patent US 10,344,086
Granted Patent B2
US 10,344,086 · App. 15/700,374 · Granted Jul 9, 2019

Antibodies to IL-6 and use thereof

Inventors: Leon F. Garcia-Martinez (Woodinville, WA); Anne Elisabeth Carvalho Jensen (Mill Creek, WA); Katie Anderson (Kirkland, WA); Benjamin H. Dutzar (Seattle, WA); Ethan W. Ojala (Snohomish, WA); Brian R. Kovacevich (Snohomish, WA); John A. Latham (Seattle, WA); Jeffrey T. L. Smith (Dublin, GB)
Assignee: ALDERBIO HOLDINGS LLC
C07K16/248C12N9/60C12N9/64C12N15/81C12P21/02A61K2039/505C07K2317/24C07K2317/34C07K2317/41C07K2317/56C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,344,086
App. No.
15/700,374
Granted
Jul 9, 2019
Kind
B2
Abstract

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Claims (21)

1. A method of producing an anti-IL-6 antibody comprising a light chain polypeptide or variable light chain polypeptide and a heavy chain polypeptide or variable heavy chain polypeptide, said method comprising culturing a recombinant yeast or mammalian cell which expresses a first nucleic acid sequence encoding said light chain polypeptide or variable light chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 20, and 651; and which recombinant cell further expresses a second nucleic acid sequence encoding a heavy chain polypeptide or variable heavy chain polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:3, 18, 19, 657, and 658.

2. The method of claim 1 wherein the first or second nucleic acid sequence is comprised of yeast or human preferred codons.

3. The method of claim 1 wherein the recombinant host cell is a mammalian cell.

4. The method of claim 1 wherein the mammalian host cell is a CHO, COS, BHK, or HEK-293 cell.

5. The method of claim 1 wherein the recombinant host cell is a yeast cell.

6. The method of claim 5 wherein the yeast cell is haploid, diploid or tetraploid.

7. The method of claim 5 wherein the yeast host cell is a Pichia cell selected from Pichia pastoris, Pichia methanolica , and Pichia angusta.

8. The method of claim 7 wherein the Pichia yeast comprise auxotrophic strains.

9. The method of claim 8 wherein said auxotrophic strains comprise P. pastoris strains met1, lys3, ura3 and ade1.

10. The method of claim 5 wherein the recombinant yeast cell is polyploidal.

11. The method of claim 1 wherein the light chain polypeptide comprises the variable light chain polypeptide of SEQ ID NO: 20 or SEQ ID NO: 651 and further comprises the kappa constant light chain polypeptide of SEQ ID NO: 586 and the heavy chain polypeptide comprises the variable heavy chain polypeptide of any one of SEQ ID NOS: 18, 19, 657 and 658 and further comprises the gamma-1 constant heavy chain of SEQ ID NO: 588.

12. The method of claim 1 wherein the light chain polypeptide comprises the variable light chain polypeptide of SEQ ID NO: 20 and further comprises the kappa constant light chain polypeptide of SEQ ID NO: 586 and the heavy chain polypeptide comprises the variable heavy chain polypeptide of SEQ ID NO: 18 and further comprises the gamma-1 constant heavy chain of SEQ ID NO: 588.

13. The method of claim 12 , wherein the recombinant host cell comprises a diploidal Pichia pastoris cell.

14. The method of claim 1 wherein the light chain polypeptide comprises the variable light chain polypeptide of SEQ ID NO: 20 and further comprises the kappa constant light chain polypeptide of SEQ ID NO: 586 and the heavy chain polypeptide comprises the variable heavy chain polypeptide of SEQ ID NO: 19 and further comprises the gamma-1 constant heavy chain of SEQ ID NO: 588.

15. The method of claim 14 , wherein the recombinant host cell comprises a diploidal Pichia pastoris cell.

16. The method of claim 1 wherein the light chain polypeptide comprises the variable light chain polypeptide of SEQ ID NO: 20 and the further comprises kappa constant light chain polypeptide of SEQ ID NO: 586 and the heavy chain polypeptide comprises the variable heavy chain polypeptide of SEQ ID NO: 657 and further comprises the gamma-1 constant heavy chain of SEQ ID NO: 588.

17. The method of claim 16 , wherein the recombinant host cell comprises a diploidal Pichia pastoris cell.

18. The method of claim 1 wherein the light chain polypeptide comprises the variable light chain polypeptide of SEQ ID NO: 20 and further comprises the kappa constant light chain polypeptide of SEQ ID NO: 586 and the heavy chain polypeptide comprises the variable heavy chain polypeptide of SEQ ID NO: 658 and further comprises the gamma-1 constant heavy chain of SEQ ID NO: 588.

19. The method of claim 18 , wherein the recombinant host cell comprises a diploidal Pichia pastoris cell.

20. The method of claim 1 wherein the recombinant cell is engineered to express protein disulfide isomerase (PDI).

21. The method of claim 11 wherein the recombinant host cell comprises a diploidal Pichia pastoris cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: H. LUNDBECK A/S
To: VITAERIS INC.
Reel/Frame 053496/0319 →
Continuity (17)
Division 13152603 · Jun 3, 2011
Continuation 12366567 · Feb 5, 2009
Continuation In Part 12323066 · Nov 25, 2008
Continuation In Part 12153612 · May 21, 2008
Continuation In Part 12153611 · May 21, 2008
Continuation In Part 12124723 · May 21, 2008
Continuation In Part 12323147 · Nov 25, 2008
Continuation In Part 12153612 · May 21, 2008
Continuation In Part 12153611 · May 21, 2008
Continuation In Part 12124723 · May 21, 2008
Continuation In Part 12323194 · Nov 25, 2008
Continuation In Part 12153612 · May 21, 2008
Continuation In Part 12153611 · May 21, 2008
Continuation In Part 12124723 · May 21, 2008
Provisional Application 60924550 · May 21, 2007
Provisional Application 60924551 · May 21, 2007
Related Publication 20180186874A1 · Jul 5, 2018